IDH突变对高级别胶质瘤的获益能否超越首次复发?一项多机构回顾性分析
这项多机构回顾性研究纳入2015至2020年病理确诊的成人高级别胶质瘤患者,121例符合标准,其中IDH突变型星形细胞瘤14例(11.6%),IDH野生型胶质母细胞瘤107例(88.4%)。IDH突变型患者首次复发平均时间显著长于IDH野生型(17.5个月 vs 9.8个月,p=0.0130),但第二次复发平均时间无显著差异(10.8个月 vs 8.1个月,p=0.176)。
要点
- IDH突变型首次复发平均时间17.5个月,显著长于IDH野生型的9.8个月(p=0.0130)。
- 第二次复发平均时间IDH突变型10.8个月 vs IDH野生型8.1个月,无显著差异(p=0.176)。
- 多变量分析显示IDH野生型(p=0.0491)和黑人种族(p=0.0238)预测首次复发时间更短。
核心结论
- IDH突变状态显著影响首次复发时间但不影响第二次复发时间,研究揭示了复发模式并突出了疾病进展的差异。
研究设计与样本
- 回顾性、多机构研究,纳入2015至2020年病理确诊的成人高级别胶质瘤患者,共319例中121例符合纳入标准。
- 高级别胶质瘤指IDH突变型WHO 3或4级星形细胞瘤和IDH野生型胶质母细胞瘤,符合WHO CNS5标准。
- 分析人口学、治疗、切除范围及分子标志物,按RANO 2.0标准计算复发时间,统计方法包括Mann-Whitney U检验、Fisher精确检验和Cox回归。
主要发现
- 121例中IDH突变型星形细胞瘤14例(11.6%),IDH野生型胶质母细胞瘤107例(88.4%)。
- 首次复发平均时间IDH突变型17.5个月 vs IDH野生型9.8个月,IDH突变型显著更长(p=0.0130)。
- 第二次复发平均时间IDH突变型10.8个月 vs IDH野生型8.1个月,无显著差异(p=0.176)。
- 多变量分析中IDH野生型(p=0.0491)和黑人种族(p=0.0238)预测首次复发时间更短。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrence is inevitable in both IDH wild-type glioblastoma and IDH-mutant WHO grade 3 or 4 astrocytoma. While IDH-mutant astrocytomas are associated with longer survival and delayed first progression, less is known about disease course beyond initial treatment. This study examines whether IDH mutation status influences time to second recurrence and identifies additional predictors of recurrence intervals. METHODS: This retrospective, multi-institutional study included adults diagnosed with pathologically confirmed high-grade glioma (HGG) between 2015 and 2020. HGG refers to IDH-mutant WHO grade 3 or 4 astrocytomas and IDH wild-type glioblastomas, consistent with WHO CNS5 criteria. Demographics, treatment, extent of resection, and molecular markers were analyzed. Time-to-recurrence was calculated per RANO 2.0 criteria. Statistical tests included Mann‒Whitney U, Fisher's exact, and Cox regression. RESULTS: Among 319 patients, 121 met inclusion criteria. Fourteen (11.6%) had IDH-mutant astrocytomas, and 107 (88.4%) had IDH wild-type glioblastomas. Mean time to first recurrence was significantly longer in IDH-mutant patients (17.5 months) than IDH wild-type (9.8 months, p = 0.0130). Mean time-to-second recurrence was not significantly different (IDH-mutant: 10.8 months, IDH wild-type: 8.1 months, p = 0.176). Multivariate analysis found IDH wild-type status (p = 0.0491) and Black race (p = 0.0238) predicted shorter time to first recurrence. CONCLUSIONS: IDH mutation status significantly affects time to first but not second recurrence. This study offers insight into recurrence patterns and highlights disparities in disease progression.
引用
- Lally AR, Ghosh SR, Pecorari IL, et al. Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysis. J Neurooncol. 2025. PMID: 40261557. doi:10.1007/s11060-025-05049-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。